Sivalingam Kanagasegar, MD
Rheumatology · Crossville, TNNPI 1982666012
Payments from drug & device makers
Across 1,306 payments — averaging $18.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$5K
- Eli Lilly$4K
- AbbVie$4K
- Johnson & Johnson$2K
- UCB, Inc.$2K
- Novartis$2K
- plus $6K from 30 others
Across 4 payments — averaging $7610.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$30K
What the payments were for
- Consulting fees$4202%
- Speaking & faculty fees$1,2006%
- Grants$2401%
- Food & beverage$18,11790%
- Education$2651%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 264 | $5,028 |
| Eli Lilly | 2 | $4,070 |
| AbbVie | 259 | $3,554 |
| Johnson & Johnson | 120 | $2,301 |
| UCB, Inc. | 166 | $1,773 |
| Novartis | 104 | $1,659 |
| Pfizer | 120 | $1,359 |
| Lilly USA, LLC | 56 | $809 |
| GSK | 27 | $560 |
| Radius Health, Inc. | 34 | $487 |
| E.r. Squibb & Sons, L.L.C. | 25 | $403 |
| AstraZeneca | 21 | $387 |
| Mallinckrodt Hospital Products Inc. | 12 | $230 |
| Genentech USA, Inc. | 18 | $201 |
| Cardinal Health 110 LLC | 2 | $200 |
| Sanofi | 10 | $182 |
| Fresenius Kabi USA, LLC | 10 | $170 |
| Regeneron Healthcare Solutions, Inc. | 11 | $159 |
| Boehringer Ingelheim | 7 | $129 |
| Bristol Myers Squibb | 8 | $123 |
| Sandoz | 6 | $117 |
| Aurinia Pharma U.S., Inc. | 4 | $70 |
| Mallinckrodt Enterprises LLC | 3 | $54 |
| Scilex Pharmaceuticals Inc. | 2 | $35 |
| Kyowa Kirin, Inc. | 2 | $33 |
| Kowa Pharmaceuticals America, Inc. | 2 | $31 |
| Avion Pharmaceuticals | 2 | $29 |
| Shorla Oncology Inc. | 1 | $26 |
| Fidia Pharma USA Inc. | 1 | $23 |
| Tersera Therapeutics LLC | 1 | $21 |
| ANI Pharmaceuticals, Inc. | 1 | $19 |
| Zimmer Biomet | 1 | $17 |
| Actelion Pharmaceuticals US, Inc. | 1 | $13 |
| Hikma Pharmaceuticals USA | 1 | $13 |
| Sobi, Inc | 1 | $13 |
| Zyla Life Sciences, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,311 in reported general payments places this provider in the 70th percentile of 127 rheumatology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 311 | $2,432,110 |
| Humira(Cf) PenAdalimumab | 228 | $1,662,035 |
| RinvoqUpadacitinib | 179 | $1,248,010 |
| Orencia ClickjectAbatacept | 92 | $524,964 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 45 | $352,435 |
| TremfyaGuselkumab | 24 | $336,208 |
| KevzaraSarilumab | 56 | $277,113 |
| Xeljanz XrTofacitinib Citrate | 42 | $256,339 |
| Cosentyx Unoready PenSecukinumab | 29 | $221,283 |
| Taltz AutoinjectorIxekizumab | 29 | $196,253 |
| OtezlaApremilast | 36 | $195,457 |
| Actemra ActpenTocilizumab | 40 | $171,734 |
| TymlosAbaloparatide | 48 | $145,879 |
| Enbrel MiniEtanercept | 20 | $143,728 |
| Cimzia (2 Pack)Certolizumab Pegol | 23 | $133,827 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Savella | $3,554 | $1,261,313193 claims |
| Johnson & JohnsonTremfya, Simponi Aria | $2,301 | $420,25036 claims |
| AmgenOtezla, Enbrel, Prolia | $5,028 | $335,13479 claims |
| SanofiKevzara | $182 | $277,11356 claims |
| Radius Health, Inc.Tymlos | $487 | $145,87948 claims |
| UCB, Inc.Cimzia (2 Pack) | $1,773 | $133,82723 claims |
| PfizerXeljanz | $1,359 | $86,63115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 127 rheumatology providers in Tennessee.
Other rheumatology in Crossville
- Jacob AelionJackson$13.2M
- Ramesh GuptaMemphis$5.5M
- Joseph HuffstutterHixson$832K
- Marcus OwenMurfreesboro$594K
- Brett SmithKnoxville$587K
- Satish OdhavJackson$527K
- Erin WilfongNashville$388K
- Robert CollinsNashville$383K
- Jason SpringerNashville$363K
- Debendra PattanaikMemphis$329K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.